We recently demonstrated that chronic treatment with brain-derived neurotrophic factor (BDNF) regulates energy expenditure in obese diabetic C57BL=KsJ-db=db mice. In this study, we investigated the acute effects of BDNF on energy expenditure. DESIGN: After BDNF was singly administered to male db=db mice (aged 10 -12 weeks), their body temperature and whole body glucose oxidation were measured. Their norepinephrine (NE) turnover and uncoupling protein (UCP) 1 expression in interscapular brown adipose tissue (BAT) were also analyzed. RESULTS: Even though the body temperatures of hyperphagic db=db mice dropped remarkably in a 24 h period after food deprivation, only a single subcutaneous administration of BDNF significantly prevented the reduction of body temperature. BDNF was also observed to have similar efficacy in cold exposure experiments at 15 C. Respiratory excretion of 14 CO 2 after intravenous injection of D-[ 14 C(U)]-glucose was significantly increased by BDNF administration, indicating that BDNF increases whole-body glucose oxidation. BDNF administered intracerebroventricularly was also able to prevent the reduction of body temperature of db=db mice. To clarify the BDNF action mechanism we examined NE turnover in BAT. Four hours after a single administration, BDNF reduced NE content in the presence of the tyrosine hydroxylase inhibitor, a-methyl-P-tyrosine methyl ester, indicating enhanced NE turnover in BAT. BDNF also increased the expression of the UCP1 mRNA and protein in BAT. CONCLUSION: These data indicate that BDNF rapidly regulates energy metabolism in obese diabetic animals, partly through activating the sympathetic nervous system and inducing UCP1 gene expression in BAT.
Introduction
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family which includes nerve growth factor, neurotrophin-3 and neurotrophin-4=5. 1 -4 BDNF promotes neurite outgrowth and provides trophic support to certain neurons during development and in adulthood. 1 The efficacy of BDNF in the treatment of neurological disorders has also been demonstrated. 5 -7 We have previously shown that subcutaneous administration of BDNF reduces food intake and lowers blood glucose to normoglycemic levels in obese diabetic models such as C57BL=KsJ-db=db mice. 8 -10 This was the first evidence that BDNF has a pleiotrophic effect and functions, even though a neurotrophic factor, in the endocrine system.
Since BDNF reduced food intake in obese and hyperphagic db=db mice, we developed a novel pellet pair-feeding apparatus to control precisely the quantity and timing of feeding between the control group and BDNF-treated group. With this apparatus we were able to demonstrate the hypoglycemic action of BDNF independently of food intake. In the repetitive daily administration of BDNF under such strict food control, we found that the control pellet pair-fed db=db mice did not receive sufficient food, resulting in lower body temperatures than the ad libitum-fed db=db mice. In addition to its hypoglycemic effect, we demonstrated that daily administration of BDNF completely ameliorated the alteration of body temperature and oxygen consumption in pairfed db=db mice. 11 However, it is not yet known whether BDNF has a direct effect on the regulation of energy metabolism. There is the possibility that energy expenditure is being affected by the hypoglycemic and hypophagic effects of long-term BDNF administration to obese diabetic animals.
Although our previous study showed that BDNF rapidly enhanced the hypoglycemic action of insulin in streptozotocin-induced type 1 diabetic mice, 11 the acute effects of BDNF on energy expenditure have not yet been investigated. In this study we thus decided to determine whether BDNF immediately affected the regulation of energy expenditure. We also discuss the analogous effects of BDNF and leptin on energy and glucose metabolisms.
Methods

Animals
Male C57BL=KsJ-db=db mice and male C57BL=6N mice were obtained from Clea Japan (Tokyo, Japan). All treatments were started at 10 -12 weeks of age. All animals were housed in group cages and maintained in a daily cycle of 12 h light and 12 h darkness. Food (CE-2, Clea Japan, Tokyo, Japan) and water were given ad libitum except for mice in the fasting experiments. All animal experiments were conducted according to the guidelines of the Sumitomo Pharmaceuticals Committee on Animal Research.
Administration of BDNF
Human recombinant BDNF (N-terminal methionine-free, Regeneron Pharmaceuticals, Tarrytown, NY, USA) was administered subcutaneously at a dosage of 20 mg=kg to db=db mice except for the norepinephrine turnover experiment. PBS (phosphate-buffered saline) containing 0.01% Tween 80 and 1% mannitol was used as the vehicle. For intracerebroventricular administration, db=db mice were anesthetized with diethyl ether, the bregma was identified, and 15mg BDNF=mouse (3 ml=shot) was injected into the lateral ventricle. Artificial cerebrospinal fluid (aCSF -0.166 g=l CaCl 2 , 7.014 g=l NaCl, 0.298 g=l KCI, 0.203 g=l MgCl 2 =6H 2 O and 2.10 g=l NaHCO 3 ) was used as the vehicle for intracerebroventricular administration.
Body temperature
Body temperature was measured using an electron thermistor (model BAT-12, Physitemp, Clifton, NJ, USA) equipped with rectal probe (RET-3, Physitemp, Clifton, NJ, USA).
Blood glucose
Blood samples were collected from tail vein, and blood glucose was measured by the Glucose C II-Test, Wako (Mutarotase-glucose oxidase method, Wako Chemical, Osaka, Japan).
Glucose oxidation db=db mice were fasted for 18 h and then given either BDNF or vehicle subcutaneously. Four hours after BDNF or vehicle treatment the mice were injected with 5 mCi of D-[ 14 C(U)]-glucose (specific activity 3.4 mCi=mmol, NEN Life Science Products, Boston, MA, USA) in 200 ml of saline via the tail vein. Immediately after the tracer injection each mouse was placed in a metabolic chamber and air was drawn at 200 ml=min through a trap containing 200 ml of 10% NaOH solution. The NaOH solution was analyzed for 14 CO 2 before and at 15, 30, 60, 90 and 120 min after the D-[ 14 C(U)]-glucose injection. Radioactive levels in the NaOH solution were determined with a liquid scintillation analyzer using the liquid scintillator, HyonicFluor (Packard, Meriden, CT, USA).
Norepinephrine turnover
The effect of BDNF on norepinephrine turnover was assessed by the method of Collins et al, 12 slightly modified by ourselves. db=db mice were subcutaneously administered with either BDNF (7, 20, 70, 200 mg=kg) or vehicle at the beginning of a dark cycle and then food was removed. Two hours after BDNF or vehicle treatment, 250 mg=kg a-methylp-tyrosine methyl ester (AMPT), an inhibitor of tyrosine hydroxylase, was intraperitoneally injected to block de novo catecholamine synthesis. The mice were decapitated 2 h after AMPT injection and the interscapular brown adipose tissue (BAT) was immediately dissected, weighed and then frozen in liquid nitrogen. The BAT was homogenized with 0.1 N perchlonic acid containing 5 mM EDTA. Homogenates were filtrated through a 0.22 mm mesh membrane to remove debris. Norepinephrine (NE) content in homogenates was measured using an HPLC system (LC-10A, Shimadzu Instrumentation, Kyoto, Japan) equipped with a column (CA-5DS, Eicom, Kyoto, Japan). Based on the results of HPLC analysis where differing amounts of NE were loaded, NE contents in homogenates were measured to be in a range wherein the peak area of eluted NE was proportional to the loaded NE.
Northern blot analysis db=db Mice were subcutaneously injected with either BDNF or vehicle at the beginning of a dark cycle and then food was removed. Animals were sacrificed 4 h after BDNF or vehicle treatment; interscapular BAT was excised and frozen immediately. RNA was prepared from the tissues with Trizol (Gibco BRL Life Technologies, Rockville, MD, USA) using the manufacturer's protocol. Yield and purity of RNA were determined by spectrophotometric absorption analysis at 260=280 nm. Three micrograms of total RNA were electrophoresed in a 1% agarose gel containing formaldehyde and then transferred to GT probe membranes (Bio-Rad Laboratories, Hercules, CA, USA). A 1071-base pair rat uncoupling protein-1 (UCP1) probe (nucleotides 84-1154 in Genebank accession no. M11814) was obtained by reverse transcriptasepolymerase chain reaction (RT-PCR) from rat BAT RNA using primers 5 0 -CCA CAG GAA TTC GAA GTT GAG AGT TCG GTA and 5 0 -CCC AGC TCT AGA GCC CAG CAT AGG AGC CCA as reported previously. 13 A 349-base pair mouse b-actin probe (nucleotides 728-1076 in Genebank accession no. M12481) was obtained by RT-PCR from mouse liver RNA using primers BDNF rapidly increases energy expenditure A Tsuchida et al 5 0 -TGG AAT CCT GTG GCA TCC ATG AAA C and 5 0 -TAA AAC GCA GCT CAG TAA CAG TCC G. All probes were verified by sequencing. Probes were randomly labeled using a BcaBest labeling kit (Takara, Ohtsu, Japan) with [a-32 P]-deoxy CTP (Amersham Pharmacia Biotech, Buckinghamshire, England). Hybridization was carried out at 65 C in 0.25 M sodium phosphate (pH 7.2)=7% SDS, and blots were washed twice with 20 mM sodium phosphate (pH 7.2)=5% SDS and then with 20 mM sodium phosphate (pH 7.2)=1% SDS. Hybridization signals were quantified using a bio-imaging analyzer BAS2000 (Fuji Photo Film, Tokyo, Japan).
Western blot analysis db=db Mice were subcutaneously injected with either BDNF or vehicle at the beginning of a dark cycle and then food was removed. Animals were killed 4 h after BDNF or vehicle treatment; interscapular BAT was excised and frozen immediately. Frozen interscapular BAT were homogenized in icecold lysis buffer (20 mM Tris -HCl (pH 7.4), 0.15 M NaCl, 1% NP-40, 0.1% sodium deoxycholate, 5 mM EDTA, 10 mM sodium fluoride, 2 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 10 mg=ml aprotinin and 10 m=ml leupepsin). Homogenates were centrifuged and protein content of supernatants was determined by BCA method using a kit (Pierce, Rockford, IL, USA). Equal protein amounts of whole tissue extracts (20 mg=lane) were resolved by SDS -PAGE (10=20% gradient polyacrylamide gels), transferred to Hybond-ECL nitrocellulose membranes (Amersham, Arlington Heights, IL, USA), and subjected to Western blot analysis using affinity-purified polyclonal rabbit antibody raised against a 19-amino acid C-terminal sequence of mouse and rat UCP1 (UCP12-A, Alpha Diagnostics International, San Antonio, TX, USA). The blots were quantified by densitometry using an chemiluminescent imaging system (DIANA, M&S Instruments Trading, Tokyo, Japan) and its analysis software (AIDA, Fuji Photo Film, Tokyo, Japan).
Statistical analysis
All data are presented as mean AE s.d. Differences between individual groups were analyzed by Student's t-test or Willliams' test. Statistical calculations were performed using SAS software (SAS Institute, Cary, NC, USA). P < 0.05 was considered statistically significant.
Results
Effect of a single administration of BDNF on body temperature in db=db mice In our previous study, control pellet pair-fed db=db mice were observed to have a lower body temperature than ad libitumfed db=db mice. It was shown there that repetitive daily administration of 20 mg=kg BDNF for 3 weeks ameliorated this reduction in body temperature. 11 In the present study we have now examined the acute effect of BDNF on energy metabolism. To investigate the effect of BDNF on body temperature independently of its hypophagic action, food was removed from db=db mice after BDNF or vehicle treatment. The body temperature of control db=db mice given vehicle was found to drop dramatically during the first 24 h period after food deprivation ( Figure 1A ). In contrast, only a single administration of 20 mg=kg BDNF significantly prevented this reduction in body temperature ( Figure 1A ). During the 24 h experiment, no significant difference was observed between the BDNF-treated and vehicle-treated groups in either body weight or blood glucose concentration ( Figure 1B, C) . Figure 1 Effect of BDNF on body temperature, body weight and blood glucose in fasted db=db mice. BDNF (20 mg=kg) or vehicle was administered subcutaneously at 0 h, and thereafter all animals were kept in a fasting condition. Body temperature (A), body weight (B) and blood glucose (C) were measured at 0, 3, 6 and 24 h after BDNF or vehicle administration. Data are shown as means AE s.d. for seven mice. *P < 0.05; **P < 0.01 vs vehicle by Student's t-test.
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The effect of BDNF on body temperature was also assessed in normal C57BL=6N mice. During the first 24 h after food removal the body temperature of normal mice slightly but significantly decreased by 1. 4 C compared with the ad libitum-fed normal mice. A single 20 mg=kg administration of BDNF did not affect body temperature in either the fasted or ad libitum-fed normal mice (data not shown).
Effect of a single administration of BDNF on body temperature in cold-exposed db=db mice A cold exposure experiment was also performed to study the effect of BDNF treatment on the body temperature of db=db mice. When the animals were placed in a cold room at 15 C with free access to food and water, body temperatures of the vehicle-treated db=db mice decreased (Figure 2 ). In contrast, only a single administration of 20 mg=kg BDNF significantly prevented this reduction of body temperature (Figure 2 ). Again there were no significant differences in blood glucose concentration and body weight between the BDNF-treated animals and vehicle-treated animals (data not shown).
Effect of a single administration of BDNF on glucose oxidation in db=db mice Since BDNF ameliorated the reduction of body temperature in fasted or cold-exposed db=db mice without affecting blood glucose concentration, it is possible that BDNF increases whole-body glucose turnover in a manner similar to the anorexic protein, leptin.
14 The production rates of respiratory CO 2 expired from the BDNF-treated db=db mice was significantly higher than the vehicle-treated db=db mice (Figure 3) . The BDNFtreated animals maintained a higher 14 CO 2 expiration rate throughout the observation period (120 min). There was no significant difference in blood glucose concentration between BDNF-and vehicle-treated mice 120 min after the tracer injection (248 AE 61.7 vs 277 AE 48.9 mg=dl). These observations indicate that BDNF increased whole-body glucose oxidation and enhanced glucose turnover without affecting blood glucose concentration.
Intracerebroventricular administration of BDNF on body temperature in db=db mice Given the possibility that the acute effect of BDNF on energy metabolism is due to direct action on the brain, we decided to investigate the effect of BDNF intracerebroventricular administration on body temperature in db=db mice. Previously we have shown that repetitive administration of 15 mg BDNF every other day reduced blood glucose concentration effectively 11 and thus chose the same dosage (15 mg) Figure 2 Effect of BDNF on body temperature of db=db mice during cold exposure. BDNF (20 mg=kg) or vehicle was administered subcutaneously at 0 h, and thereafter all animals were placed in a cold room at 15 C with ad libitum access to food and water. Body temperature was measured at the indicated times after BDNF or vehicle administration. Data are shown as means AE s.d. for five mice. **P < 0.01 vs vehicle by Student's t-test. 
A Tsuchida et al of BDNF for this single intracerebroventricular administration. Since hypophagia was also observed with intracerebroventricular administration, food was removed from db=db mice after BDNF or vehicle treatment. Although the body temperature of db=db mice given intracerebroventricular vehicle dropped during the 24 h period after food deprivation, only a single intracerebroventricular administration of 15 mg BDNF=mouse (approximately 300 mg=kg) significantly blocked the reduction of body temperature (Figure 4 ).
Effect of a single administration of BDNF on norepinephrine turnover
Our finding that intracerebroventricular administration of BDNF acutely stimulated thermogenesis led us to hypothesize that BDNF activates the sympathetic nervous system and regulates energy expenditure. We thus analyzed norepinephrine (NE) turnover in BAT, a predominant thermogenic organ in mice, to assess the effect of BDNF on the sympathetic nervous system. To determine NE turnover we measured the decrease of NE content in BAT before and after injection of a tyrosine hydroxylase inhibitor, a-methyl-ptyrosine methyl ester (AMPT), which inhibits de novo catecholamine synthesis. db=db mice were given BDNF (7, 20, 70, 200 mg=kg, s.c.) or vehicle and 2 h later injected with AMPT. Two hours after the AMPT injection, NE content in BAT of the db=db mice was measured by HPLC. As a zero-time control, NE content in BAT of db=db mice before AMPT injection was also measured. NE content in BAT of db=db mice given vehicle was reduced to 73% of the zero-time control by AMPT inhibition of catecholamine synthesis ( Figure 5 ). NE content in BAT of db=db mice given BDNF decreased in a dose-dependent manner. Administration of BDNF at a dose of higher than 20 mg=kg significantly reduced NE content compared with that of mice given vehicle ( Figure 5 ). These results indicate that BDNF acutely increased NE turnover in BAT.
Effects of a single administration of BDNF on expression of uncoupling protein 1 mRNA and protein in BAT To clarify the action mechanism by which BDNF stimulates the glucose and energy metabolisms, we examined the expression of UCP1 gene as an indicator of sympathetic nerve activity in BAT and the effect of BDNF on that. BDNF (20 mg=kg) or vehicle was administrated subcutaneously to db=db mice and followed by food removal. Total RNA was prepared from BAT 4 h after BDNF or vehicle administration. Northern blot analysis of BAT RNA (3 mg) showed that a single administration of BDNF significantly recovered UCP1 mRNA levels, which was 2.6-fold higher than vehicletreated animals without food supply ( Figure 6A) .
We also studied the UCP1 protein expression in BAT from the same animals used in Northern blot analysis. The extracts of whole tissues (20 mg=lane) was analyzed with SDS -PAGE, followed by Western blotting using anti-UCP1 antibody. Again, BDNF significantly increased the expression of UCP1 protein in BAT by 1.6-fold ( Figure 6B ). Effect of BDNF on norepinephrine turnover in brown adipose tissue. BDNF or vehicle was administered subcutaneously to db=db mice followed by food removal. Two hours after BDNF or vehicle administration, 250 mg=kg a-methyl-p-tyrosine methyl ester (AMPT) was injected intraperitoneally. Mice were then decapitated 2 h after AMPT injection and norepinephrine (NE) content of the interscapular brown adipose tissue (BAT) was measured by HPLC. As a zero-time control, NE content in BAT of db=db mice before AMPT injection was also measured. Data are shown as means AE s.d. for 10 mice. **P < 0.01 vs vehicle by Willliams' test. ##P < 0.01 vs zero-time control by Student's t-test.
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A Tsuchida et al Discussion db=db mice are obese and hyperphagic diabetic animals with impaired glucose and energy metabolisms. 15 -17 Discoveries of leptin and its receptor (Ob-R) led to identification of a mutation in the Ob-R gene of db=db mice. 18, 19 This was subsequently determined to be the cause for the obesity and resistance to leptin treatment. 20, 21 In our previous studies it was found that BDNF reduces both food intake and blood glucose in db=db mice. 8 -11 In order to investigate the effect of BDNF on glucose metabolism independently of alteration in food intake we developed a novel pellet-pair feeding apparatus to supply the same quantity of food to both control mice and BDNF-treated mice. In the 3 week study of repetitive daily BDNF administration it was found that pair-fed control db=db mice receiving a restricted quantity of food had significantly lower body temperatures and oxygen consumption than ad libitum-fed db=db mice. 11 This indicates that db=db mice require excessive food intake to maintain their body temperature possibly due to reduced energy expenditure, although the body temperature of ad libitum-fed db=db mice is still lower than normoglycemic db=db mice.
In spite of the reduced food intake, to our surprise, db=db mice receiving BDNF daily could maintain nearly the same body temperature and metabolic rate as ad libitum-fed db=db mice. 11 These findings indicate that BDNF ameliorated the erratic energy balance characteristic of db=db mice. However, we have also demonstrated that daily administration of BDNF reduces the blood glucose of db=db mice. 11 Since the attenuation of glucose toxicity improves various types of metabolic dysfunction in diabetic animals, 22 we felt that the improvement of energy expenditure might be due to the hypoglycemic action of BDNF. Therefore, in order to understand the effect of BDNF on glucose and energy metabolisms in greater detail, we investigated the acute effect of a single administration of BDNF in the present study.
During periods of food deprivation or cold-exposure, only a single administration of BDNF prevented the reduction of body temperature in db=db mice without affecting blood glucose concentration. Also, 4 h after BDNF administration, glucose oxidation was enhanced. These data clearly demonstrate that BDNF has an immediate, direct effect on the regulation of energy expenditure in diabetic mice. In addition to db=db mice, BDNF reduces food intake and blood glucose concentration in ob=ob mice and KKAy mice (data not shown). Furthermore, in our unpublished study, BDNF prevented reduction of body temperatures in monosodium glutamate (MSG)-induced obese rats under fasted condition. Therefore, we consider that BDNF's effect is not specific for db=db mice. On the other hand, BDNF did not affect the body temperature of normoglycemic C57BL=6N mice in either fed or fasted conditions (data not shown). Furthermore, as we previously reported, BDNF does not reduce blood glucose concentration in normoglycemic mice. 8 Taken together, these results indicate that BDNF may not affect the energy metabolism of normoglycemic animals.
In our previous study, both a hypoglycemic effect and appetite reduction were also observed with repetitive intracerebroventricular administration of BDNF in db=db mice.
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This suggests the possibility that the hypoglycemic effect is due to the direct action of BDNF on the central nervous system. Furthermore, this study showed that a single central administration of BDNF at a dose too low to have an effect when delivered peripherally was able to immediately ameliorate the reduction of body temperature. Since the BDNF receptor, trk B, has been shown to be expressed in hypothalamic nucleuses, 23 it seems reasonable to speculate that BDNF administrated peripherally enters the hypothalamus by crossing the blood -brain barrier (BBB) and regulates energy metabolism and appetite at this region. In fact, it has been reported that BDNF in the peripheral circulation crosses the BBB and reaches the central nervous system. 24, 25 In addition to these pharmacological profiles of BDNF, it has been reported that mice that are heterozygous for targeted disruption of the BDNF gene exhibit hyperphagia and obesity. 26, 27 This suggests the physiological significance of BDNF in weight control and glucose metabolism.
Our findings thus reveal that the actions of BDNF are strikingly similar to those of leptin in their effect on body temperature, oxygen expenditure and food intake. The role of leptin in the regulation of energy metabolism and food intake has been well documented. 20, 21, 28 Since the leptin BDNF rapidly increases energy expenditure A Tsuchida et al receptor, Ob-R, is expressed in the hypothalamus, it has been suggested that leptin secreted peripherally from adipose tissue acts on the hypothalamus, 29 -31 the regulatory center of autonomic nervous system controlling both food intake and energy expenditure. 32 Although BDNF receptor, trk B is also found in the hypothalamic region of rat brain, 23 it has not been reported so far whether some hypothalamic neurons may share expression of trk B and leptin receptor or not.
The autonomic nervous system is involved in processes where brain controls energy metabolism. 33 For example, activation of the sympathetic nervous system leads to increases of gluconeogenesis and glycogenolysis in liver, glucose uptake in skeletal muscles, and thermogenesis and glucose uptake in BAT. 33 In our present study BDNF decreased NE content in BAT of db=db mice given the blocker of catecholamine synthesis, AMPT. On the other hand BDNF did not affect NE content in BAT without AMPT injection (our unpublished data). These results have clearly shown that BDNF does not block de novo catecholamine synthesis, but that BDNF increases NE turnover in BAT. It has been reported that NE turnover is enhanced either by leptin administration or electrical stimulation of the ventromedial hypothalamic nucleus (VMH). 12, 34 Therefore, the observed increase in energy metabolism in BDNF-treated db=db mice could be the result of adrenergic activation in BAT. This, taken together with our finding that intracerebroventricular administration of BDNF also regulates energy metabolism, strongly supports our hypothesis that BDNF modulates energy metabolism through its effect on hypothalamic nuclei and the autonomic nervous system which in turn activate neuronal regulation of the energy metabolism.
Uncoupling protein (UCP) is a mitochondrial protein which regulates energy expenditure including thermogenesis. Among the several UCPs known so far, UCP1 is expressed specifically in BAT and has a significant role in maintaining body temperature in rodents. It has been reported that 4 h after leptin treatment the expression of UCP1 mRNA was rapidly increased in BAT. 35 It has also been shown that treatment with b3-adrenergic agonists resulted in increase of UCP1 mRNA levels in BAT. 36 Our results indicate that BDNF also increased UCP1 mRNA and UCP1 protein expression in BAT. Expression level of UCP1 in BAT of db=db mice was reported to be comparable with that of lean control mice under ad libitum-fed condition. 37 Since body temperatures of db=db mice given vehicle dropped after food removal in our present study, it is likely that sympathetic nerve activity was suppressed and UCP1 expression in BAT was reduced. BDNF may compensate such suppression and normalize energy expenditure of db=db mice.
In addition to its effect on energy metabolism and food intake, it has been reported that leptin also shows a hypoglycemic effect in some disease models. 38, 39 This lends more evidence to support our belief that the efficacy of leptin is very similar to BDNF. Further studies, similar to those done with leptin, will be needed to evaluate the molecular mechanism by which BDNF regulates energy expenditure and glucose metabolism. In conclusion, we have shown that BDNF is an immediate and direct modulator of energy expenditure and glucose metabolism in obese diabetic animals. This supports our belief that BDNF may be a potentially useful therapeutic agent for diabetic mellitus and obesity.
